JOURNAL OF INTERNATIONAL MEDICAL RESEARCH AND HEALTH SCIENCES - Volume 1 Issue 1, (Apr-Jun, 2021)

Pages: 16-22

Anemia in elderly patients–Etiology and morphologies in northern region of India

Anil Batta

Category: Biomedicine

Download PDF

Abstract:

Anemia in elders is an extremely common problem which results in which can be caused by mortality and morbidity, particularly in the elderly age group. At this age, it can be more devastating than youngsters. According to WHO study occurrence of anemia is 10.2% in women and 11% in men aged 65% or more. Approximately one-third of cases have anemia due to nutritional deficiency, one-third due to chronic inflammation and chronic kidney disease or both and one-third have unexplained anemia. Reduction of RBC production due to bone marrow suppression can also lead to anemia. This is seen in side effects of medication, myelodysplasia, and decreased bone marrow production associated with ageing. For all practical purposes diagnosis of anemia is diagnosed due to three parameters hemoglobin (Hb), hematocrit value (Hct), and RBC count. Clinical symptoms of anemia can be fatigue, dizziness, tachycardia, dyspnoea, head and chest pain, cold hands and feet, restless leg syndrome, and tarry stools.

Keywords: Bone marrow, RBC count, hematocrit value, fatigue, dyspnoea, restless leg syndrome, tarry stools

References:

[1] Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues (Revised 4th edition). Lyon, France: IARC; 2017.

[2] Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006; 20(9):1641-4.

[3] Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006; 108(7):2173-81.

[4] Gurevich I, Luthra R, Konoplev SN, Yin CC, Medeiros LJ, Lin P. Refractory anemia with ring sideroblasts associated with marked thrombocytosis a mixed group exhibiting a spectrum of morphological findings. Am J ClinPathol. 2011; 135(3):398-403.

[5] Taylor G, Culligan D, Vickers MA. Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia. Case Rep Hematol. 2013; 2013:718480.

[6] Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, et al. Clinical features and course of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Hematologica. 2012; 97(7):1036-41.

[7] Schnittger S, Bacher U, Haferlach C, Dengler R, Kröber A, Kern W, et al. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia. 2008; 22(2):453-5.

[8] Raya JM, Arenillas L, Domingo A, Bellosillo B, Gutiérrez G, Luño E, et al. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status. Int J Hematol. 2008; 88(4):387-5.

[9] Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Ki et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008; 93(1):34-40.

DOI: 2021.1103

DOI URL: http://doi.org/10.53626/JIMRHS.2021.1103